Oncolytics Biotech Inc. to Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
CALGARY, June 4 /PRNewswire-FirstCall/ -- Oncolytics Biotech
Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that Dr.
Brad Thompson, President and CEO, will host a conference call and
webcast on Monday, June 7th, 2010 at 7:00 a.m. MT (9:00 a.m. ET) to
discuss the Phase I/II head and neck cancer data being presented
that day at the ASCO Annual Meeting in Chicago, IL.
To access the conference call by telephone, dial 1-647-427-7450
or 1-888-231-8191. A live audio webcast will also be available at
the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3108600
or through the Company's website at www.oncolyticsbiotech.com.
Please connect at least 15 minutes prior to the webcast to ensure
adequate time for any software download that may be needed. A
replay of the webcast will be available at
www.oncolyticsbiotech.com and will also be available by telephone
through June 14th, 2010. To access the telephone replay, dial
1-416-849-0833 or 1-800-642-1687 and enter reservation number
80060184 followed by the number sign.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on
the development of oncolytic viruses as potential cancer
therapeutics. Oncolytics' clinical program includes a variety of
human trials including a Phase III trial in head and neck cancers
using REOLYSIN, its proprietary formulation of the human reovirus.
For further information about Oncolytics, please visit:
www.oncolyticsbiotech.com.
The presentation time is subject to change. This press release
and the presentations related thereto contain forward-looking
statements, within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements,
including the timing, implication and accuracy of materials
presented at the ASCO meeting with respect to REOLYSIN, and the
Company's belief as to the potential of REOLYSIN as a cancer
therapeutic, involve known and unknown risks and uncertainties,
which could cause the Company's actual results to differ materially
from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and
resources to pursue research and development projects, the efficacy
of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN
outside a controlled test, the success and timely completion of
clinical studies and trials, the Company's ability to successfully
commercialize REOLYSIN, uncertainties related to the research and
development of pharmaceuticals and uncertainties related to the
regulatory process. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties
relating to the forward-looking statements. Investors are cautioned
against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking
statements, except as required by applicable laws.
Source: Oncolytics Biotech Inc.
CONTACT: The Equicom Group, Nick Hurst, 300 5th Ave. SW, 10th
Floor,
Calgary, Alberta, T2P 3C4, Tel: (403) 218-2835, Fax: (403)
218-2830,
nhurst@equicomgroup.com; The
Investor Relations Group, Erika Moran, 11 Stone
St, 3rd Floor, New York, NY 10004, Tel: (212) 825-3210, Fax: (212)
825-3229,
emoran@investorrelationsgroup.com
Posted: June 2010
